CERO Therapeutics Reports Positive Phase 1 Safety and Early Efficacy Signals for CER-1236, Expands Trial to MDS/MF
CERO is trading near its 52-week low of $0.05 (10.0% above the low) on light trading volume (0.2× avg).
Summary
CERO Therapeutics announced positive safety data and an encouraging early efficacy signal from its Phase 1 trial of CER-1236, leading to an expansion of the trial to include additional indications like advanced MDS and myelofibrosis.
Key Events · Product Development and Regulatory · CERO
-
Positive Phase 1 Safety Data
The CertainT-1 trial reported robust cell expansion with no cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or other treatment-related adverse events in all four patients to date.
-
Early Efficacy Signal Observed
A patient with myelodysplastic syndrome (MDS) progressing to AML experienced a 61-day platelet transfusion-free interval after CER-1236 treatment, exceeding a commonly referenced 8-week benchmark for durable platelet transfusion independence.
-
Trial Expanded to New Indications
The company amended the CertainT-1 protocol with the FDA to include advanced MDS and myelofibrosis (MF) as additional cohorts for the study, indicating confidence in CER-1236's potential across a broader range of hematologic malignancies.
-
Analyst Call Scheduled
CERO Therapeutics will host an analyst call to discuss the progress and the company's go-forward strategy following this clinical update.
Analysis · CERO · Life Sciences
This 8-K filing is highly important for CERO Therapeutics as it provides a positive clinical update on its lead product candidate, CER-1236, from its ongoing Phase 1 CertainT-1 trial. The reported robust cell expansion with no serious adverse events (CRS, ICANS) is a critical safety milestone for a cell therapy. The observation of a 61-day platelet transfusion-free interval in a patient with advanced MDS/AML is an encouraging early efficacy signal, especially given the difficulty in treating these conditions. This positive data has led to a strategic expansion of the trial to include advanced MDS and myelofibrosis, broadening the potential market for CER-1236. For a company of this size, such clinical progress significantly de-risks the development program and could attract further investor interest.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CERO was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.05 to $410,000.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.